Extrait de plante de Grande camomille
Food supplement declared in France, declaration No 2021-2-706, decision dated 12 February 2021
Extrait de plante de Grande camomille (ladrôme laboratoire) is a food supplement declared in France. Status: declared in France, may be marketed. Main ingredients: Tanacetum parthenium 3.1 g per day. None of the rules we check flags an issue with its declared composition.
- Brand
- ladrôme laboratoire
- Food business operator placing the product on the market
- LA DROME PROVENCALE
- Status
- Declared in France, may be marketed: the authorities did not object to the declaration (this is neither an authorisation nor a safety assessment)
- Form
- Dropper
- Daily dose
- 3,1 g
- Directions for use
- 20 à 25 gouttes diluées dans un verre d'eau de 20 cl, 3 fois par jour, pendant 3 semaines.
- Intended populations
- Adolescents aged 11 to 17, People over 60, Men, Women
- Not recommended (according to the manufacturer)
- Breastfeeding women, Young children (aged 1 to 3), Pregnant women, Infants (under 1 year)
- Objectives stated by the manufacturer (these are not authorised claims)
- Blood and lymphatic circulation, Mood
Declaration 306646, procedure Article 15. Compl'Alim, food supplement declarations (France), retrieved 15 November 2026.
Declared composition
Plants
| Plant | Part | Preparation | Per day |
|---|---|---|---|
| Tanacetum parthenium (L.) Sch.Bip. | Parties aériennes | Extrait fluide hydroalcoolique | 3.1 g |
List from the declaration, administrative decision dated (Compl'Alim, food supplement declarations (France)).
Label warnings
Ne pas dépasser la dose journalière indiquée. Tenir hors de portée des enfants. Déconseillé aux enfants de moins de 6 ans. Ne pas utiliser pendant la grossesse et l’allaitement.
Regulatory points
None of the rules we check applies to the declared ingredients.
This information reproduces the manufacturer's declaration to the administration (DGAL). It does not say whether the product is effective and does not replace advice from a doctor or pharmacist, particularly during pregnancy or when taking medication.
Official warnings (Health Canada)
Health Canada publishes warnings on these ingredients:
- Tanacetum parthenium (L.) Sch.Bip.
Read the warning, when it applies and the studies cited
FEVERFEW - TANACETUM PARTHENIUM
Route of administration: Oral
Cautions and warnings
Condition of application: All products.
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking blood thinners (Brinker 2010; Biggs et al. 1982).
Sources cited by Health Canada (2)
- Biggs MJ, Johnson ES, Persaud NP, Ratcliffe DM. Platelet aggregation in patients using feverfew for migraine. Lancet 1982;320(8301):776. PubMed
- Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
Applies to products providing 250 mg or less of dried herb top and/or leaf, per day.
Ask a health care practitioner/health care provider/health care professional/doctor/ physician before use if you are breastfeeding (Boon 2000).
Sources cited by Health Canada (1)
- Boon H. Feverfew. In: Chandler F, editor. Herbs: Everyday Reference for Health Professionals. Ottawa (ON): Canadian Pharmacists Association and the Canadian Medical Association; 2000.
Contraindications
Applies to products providing 250 mg or less of dried herb top and/or leaf, per day.
Do not use if you are pregnant (Gardner and McGuffin 2013; Brinker 2010).
Sources cited by Health Canada (2)
- Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
- Gardner Z, McGuffin M, editors. American Herbal Products Association's Botanical Safety Handbook. Second Edition. Boca Ration (FL): Taylor and Francis Group; 2013.
Applies to products providing more than 250 mg of dried herb top and/or leaf, per day.
Do not use if you are pregnant or breastfeeding (EMA 2020).
1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).
Known adverse reactions
Condition of application: All products.
Stop use if hypersensitivity/allergy occurs (EMA 2020; Paulsen et al. 2001; Hausen 1996).
Sources cited by Health Canada (2)
1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).
When using this product you may experience sore mouth, mouth ulcers and/or gastrointestinal discomfort/disturbances (EMA 2020; Gardner and McGuffin 2013; Murphy et al. 1988; Johnson et al. 1985).
Sources cited by Health Canada (3)
- Gardner Z, McGuffin M, editors. American Herbal Products Association's Botanical Safety Handbook. Second Edition. Boca Ration (FL): Taylor and Francis Group; 2013.
- Johnson ES, Kadam NP, Hylands DM, Hylands PJ. 1985. Efficacy of feverfew as prophylactic treatment of migraine. British Medical Journal 291(6495):569-573.
- Murphy JJ, Heptinstall S, Mitchell JR. Randomized double-blind placebo-controlled trial of feverfew in migraine prevention. Lancet 1988;332(8604):189-192.
1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).
They concern the ingredient, not this product or its dose. They do not replace medical advice.
Other declarations with the same name
In France, every company that markets a supplement declares it, so one product can have several declarations (new formula, another distributor, an older declaration withdrawn). Each line compares the declared composition with this page.
- extrait de plante de grande camomille QUERCUS, declared in 2020 : different composition: 1 ingredient(s) added, 0 missing
Brand : ladrôme laboratoire
Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.
Cite this page: CompoAtlas, “Extrait de plante de Grande camomille (ladrôme laboratoire): composition and regulation”, https://compoatlas.com/en/supplements/products/306646-extrait-de-plante-de-grande-camomille, updated 15 November 2026.